Results 91 to 100 of about 428 (116)
Some of the next articles are maybe not open access.
Indications and Limitations of Afamelanotide for Treating Vitiligo
JAMA Dermatology, 2015ontheuseofafamelanotideincombinationwithnarrowbandUV-Bfor treating vitiligo. So far, there is no truly satisfactory treat-mentforvitiligo,soanynewapproachismostwelcome.How-ever,thisstudyraisesseveralissues.Afamelanotidebindswiththemelanocortin-1receptor(MC1R),whichisthereceptorup-streamofoneofthekeypathwaysformelanogenesis.
openaire +2 more sources
Afamelanotide for the treatment of erythropoietic protoporphyria
Expert Opinion on Orphan Drugs, 2013Introduction: Erythropoietic protoporphyria (EPP) is characterized by incapacitating pain in the sunlight-exposed skin areas due to accumulation of the metabolite protoporphyrin. Until now, no effective prevention of phototoxicity has been available. Afamelanotide, an α-melanocyte-stimulating hormone (α-MSH) analogue and first-in-class drug, induces ...
openaire +1 more source
British Journal of DermatologyAbstract Background Patients with erythropoietic protoporphyria experience lifelong painful photosensitivity resulting in a lack of sunlight exposure. Previous studies have shown that 47–63% of patients with EPP suffer from vitamin D deficiency and a high prevalence of osteoporosis.
Janneke Langendonk +2 more
exaly +3 more sources
Afamelanotide for treating erythropoietic protoporphyria [PDF]
, 2017 The company submission (CS) presents evidence of the clinical and cost effectiveness of afamelanotide (SCENESSE®) for adult patients with erythropoietic protoporphyria (EPP) above the age of 18 years old compared to best supportive care. In all studies afamelanotide (16 mg) was given as a subcutaneous implant.
Lord, Joanne +5 more
openaire
Journal of drugs in dermatology : JDD, 2023
Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an α-melanocyte-stimulating hormone analogue, was approved in the United States for treatment of EPP.
Sydney R, Resnik +2 more
openaire +1 more source
Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an α-melanocyte-stimulating hormone analogue, was approved in the United States for treatment of EPP.
Sydney R, Resnik +2 more
openaire +1 more source
Clinical Pharmacokinetics, 2017
Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant ...
Elisabeth I, Minder +2 more
openaire +2 more sources
Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant ...
Elisabeth I, Minder +2 more
openaire +2 more sources
Clinical and Experimental Dermatology
Erythropoietic protoporphyria (EPP) is a rare but severely debilitating photodermatosis triggered by exposure to visible and longwave ultraviolet A light, causing intense and prolonged pain that leads to extreme sunlight avoidance and a markedly reduced quality of life.
Robert S Dawe +5 more
openaire +2 more sources
Erythropoietic protoporphyria (EPP) is a rare but severely debilitating photodermatosis triggered by exposure to visible and longwave ultraviolet A light, causing intense and prolonged pain that leads to extreme sunlight avoidance and a markedly reduced quality of life.
Robert S Dawe +5 more
openaire +2 more sources
Afamelanotide in the Treatment of Dermatologic Disease
Skin therapy letterAfamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE ...
Morgan M, McNeil +3 more
openaire +1 more source